This study is looking for people aged 18 and older with cytopenia (low blood counts) or suspected/confirmed Myelodysplastic Syndromes (MDS). The goal is to develop a new, less invasive diagnostic test called PERIBLOOD-MDS. Currently, MDS is diagnosed using a bone marrow biopsy, which can be uncomfortable. This study will analyze your peripheral blood (blood from a vein, like a regular blood draw) to see if it can accurately diagnose MDS, count blast cells (immature blood cells), and check your chromosomes (karyotype). Your blood will be analyzed at the Weizmann Institute of Science. The researchers hope this new test can reduce the need for bone marrow evaluations. The study aims to enroll 1500 participants and is currently unclear on its recruitment status.

Study design

This is an observational study involving 1500 planned participants. It aims to collect data to develop a new diagnostic tool.

What's involved

You would have a peripheral blood sample taken, which will then be analyzed. The study's primary endpoint is measured three months after the blood sample.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured three months following the peripheral blood sample.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.